ProCE Banner Activity

Premium Education

CE

Managing Chemotherapy-Induced Nausea and Vomiting and Oral Anti-Cancer Adverse Effects

Video

1.25 Nursing contact hours

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: August 23, 2022

Expiration: August 23, 2024

Course Fee

$30.00

Share

Additional Information

Program Medium

This program has been made available online.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities?
 

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

Chemotherapy-induced nausea and vomiting (CINV) and other oral chemotherapy related adverse events are commonly feared by patients. Pharmacists and nurses provide many important services in caring for these patients. It is important to be able to recognize CINV risk factors and know the antiemetic therapies available for the patients. The development of a large number of targeted therapies for cancer in the past decade has led to new mechanism-based adverse effects of new drug classes that affect virtually every organ system in the body. The role of the pharmacist and nurse is to provide patient and family education, healthcare provider education, side effect prevention and management. This activity provides an update for pharmacists and nurses on the antiemetic therapies available and techniques for managing the unique adverse events associated with oral chemotherapy.

Target Audience

The target audience for this activity includes pharmacists and nurses.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify chemotherapy-induced nausea and vomiting (CINV) risk factors.
  • List the antiemetic therapy agents available for the management of CINV.
  • Recognize unique adverse effects associated with oral anti-cancer agents.
  • Formulate effective strategies to assess and select appropriate supportive care management options for adverse effects related to oral anti-cancer agents.

Faculty

Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington

The planners and content peer reviewers from ProCE, LLC and NASP do not have any relevant financial relationships to disclose.

CME/CE Accreditation

Release Date: August 23, 2021
Expiration Date: August 23, 2024

ACPE Credit Designation (Pharmacist CE)This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-169-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Fees are required for this activity.
 


Joint Accreditation StatementIn support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 Nursing Continuing EducationThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
 

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Megan May has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Gabriela Ziccarelli does not have any relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.
Laly Havern does not have any relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Laly Havern, PharmD, MS, BCACP.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

This activity is self-funded by NASP. The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.